(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

Recruiting N/A Interventional Study
Epiretinal Membrane Dry Age Related Macular Degeneration Macular Abnormalities Retina Disease Vitreoretinal Abnormality Intraretinal Hyporeflective Space Subretinal Hyporeflective Space IS/OS (Ellipsoid Zone) Disruption Retinal Pigment Epithelium (RPE) Elevation Retinal Pigment Epithelium (RPE) Atrophy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
400 (estimated)
Sponsor
Carl Zeiss Meditec-Dublin CoCe · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Able and willing to make the required study visits. 2. Able and willing to give written informed consent and follow study instructions. 3. Able and willing to complete ophthalmic imaging. 4. Adults 18 years of age or older. The subject population will be comprised of two gro…
Contacts

Patricia Sha, Optometrist

925-307-1588

patricia.sha@zeiss.com

CONTACT